L-Threonine
|
Basic information |
| Metabolite name | L-Threonine |
 | HMDB0000167 |
 |
C00188 |
 |
6288 |
| Synonyms | Threonine |
| No. of studies | 51 |
|
Basic information |
| Metabolite name | L-Threonine |
| HMDB0000167 |
|
C00188 |
|
6288 |
| Synonyms | Threonine |
| No. of studies | 51 |
|
Relationship between L-Threonine and depression (count: 51) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M002 | Type1 | CUMS group vs. control group | Thalamus | Sprague-Dawley rat | Up |
| Study M002 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M003 | Type1 | day 9 CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M013 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Up |
| Study M015 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M015 | Type2 | CUMS + Xiaoyaosan Bei group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M015 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M015 | Type2 | CUMS + Xiaoyaosan Nan group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M026 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Down |
| Study M033 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Down |
| Study M066 | Type2 | CUMS + middle dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M066 | Type2 | CUMS + venlafaxine group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M066 | Type2 | CUMS + low dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M067 | Type1 | naturally-occurring depression group vs. control group | Serum | Cynomolgus monkey | Down |
| Study M076 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M076 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M076 | Type2 | CUMS + Anemarrhena saponins and Lilium saponins group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M087 | Type2 | esketamine group 2-h vs. baseline | Plasma | Human | Down |
| Study M087 | Type2 | ketamine group 2-h vs. baseline | Plasma | Human | Down |
| Study M1019 | Type1 | depression group vs. control group | Serum | Human | Down |
| Study M1043 | Type1 | late-life depression group vs. control group | Serum | Human | Down |
| Study M111 | Type3 | WT-Scop group vs. WT-Veh group | Plasma | C57BL/6 mouse | Down |
| Study M1143 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M131 | Type1 | LH group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M204 | Type1 | LPS group vs. control group | Hypothalamus | CD-1 mouse | Up |
| Study M207 | Type1 | depressed group vs. control group | Serum | Kunming mouse | Down |
| Study M454 | Type1 | vascular depression model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M472 | Type3 | (2S,6S)-HNK group vs. control group | PC12 cell | Rat | Down |
| Study M492 | Type1 | ACTH group vs. control group | Urine | Wistar rat | Down |
| Study M492 | Type2 | ACTH + CGA group vs. ACTH group | Urine | Wistar rat | Up |
| Study M492 | Type2 | ACTH + memantine group vs. ACTH group | Urine | Wistar rat | Up |
| Study M510 | Type1 | HSD group vs. control group | Serum | Human | Down |
| Study M522 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Unknown |
| Study M536 | Type1 | naturally-occurring depression group vs. control group | Cerebrospinal fluid | Cynomolgus monkey | Up |
| Study M539 | Type1 | LPS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M540 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M543 | Type1 | summer depression group vs. summer control group | Plasma | Human | Down |
| Study M547 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M564 | Type1 | ACTH group vs. control group | Urine | Wistar rat | Down |
| Study M571 | Type1 | LPS group vs. control group | Hypothalamus | CD-1 mouse | Up |
| Study M577 | Type1 | male depression group vs. male control group, aged 30-39 | Urine | Human | Unknown |
| Study M577 | Type1 | male depression group vs. male control group, aged 40-49 | Plasma | Human | Unknown |
| Study M577 | Type1 | male depression group vs. male control group, aged 30-39 | Plasma | Human | Unknown |
| Study M602 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M610 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M610 | Type1 | CUMS group vs. control group | Heart | Sprague-Dawley rat | Up |
| Study M611 | Type1 | LPS group vs. control group | Liver | Sprague-Dawley rat | Unknown |
| Study M611 | Type1 | LPS group vs. control group | Serum | Sprague-Dawley rat | Unknown |
| Study M611 | Type1 | LPS group vs. control group | Kidney | Sprague-Dawley rat | Unknown |
| Study M613 | Type1 | CSDS susceptible group vs. control group | Nucleus accumbens | C57BL/6 J mouse | Down |
| Study M631 | Type1 | CUMS group vs. control group | Serum | Kunming mouse | Down |
| Study M631 | Type2 | CUMS + high dose of iridoid-rich fraction of V. jatamansi group vs. CUMS group | Serum | Kunming mouse | Up |
| Study M632 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Unknown |
| Study M693 | Type1 | SDS group vs. control group | Plasma | C57BL/6J mouse | Down |
| Study M756 | Type1 | depression group vs. control group | Serum | Human | Up |
| Study M779 | Type4 | remitter group vs. non-remitter group, at baseline | Plasma | Human | Down |
| Study M791 | Type1 | CUMS group vs. control group | Cecum | Sprague-Dawley rat | Down |
| Study M821 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M828 | Type1 | ultrasonic radiation group vs. control group | Frontal cortex | Wistar rat | Down |
| Study M870 | Type2 | CRS + middle dose of Jia Wei Xiao Yao San group vs. CRS group | Brain | C57BL/6 mouse | Up |
| Study M873 | Type1 | ovariectomy + CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M873 | Type2 | ovariectomy + CUMS + Xiang-Su volatile oil group vs. ovariectomy + CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M882 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M908 | Type3 | post-ketamine treatment vs. baseline | Cerebrospinal fluid | Human | Down |
| Study M928 | Type1 | CUMS group vs. control group | Prefrontal cortex | C57BL/6 mouse | Down |
| Study M928 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Up |
| Study M935 | Type2 | chronic social isolation + tianeptine group vs. chronic social isolation group | Hippocampus | Wistar rat | Up |
| Study M943 | Type1 | CUMS group vs. control group | Liver | ICR mouse | Down |
| Study M943 | Type2 | CUMS + high dose of Acanthopanax senticosus Harms group vs. CUMS group | Liver | ICR mouse | Up |
| Study M943 | Type2 | CUMS + middle dose of Acanthopanax senticosus Harms group vs. CUMS group | Liver | ICR mouse | Up |
| Study M943 | Type2 | CUMS + fluoxetine group vs. CUMS group | Liver | ICR mouse | Up |
| Study M962 | Type2 | 24h-post ketamine infusion vs. baseline | Plasma | Human | Up |
| Study M981 | Type2 | Abeta oligomer + involuntary and voluntary running + acousto-optic stimulation group vs. Abeta oligomer group | Serum | ICR mouse | Up |